Astrea Bio expands US manufacturing and warehousing capacity to cater to growing demand
Astrea Bioseparations will expand its manufacturing and warehousing capabilities in the US. The increased capacity reflects growing demand for the Company’s chromatography solutions in North American markets.
Astrea Bio is a leading provider of bioseparation and purification technologies that help to improve patient outcomes with safer and more effective production of therapeutics
The new ~12,000 sq. ft. facility will enable Astrea Bio to bring its innovative products to customers within record lead times of 3-5 weeks for off-the-shelf products, and 6-8 weeks for large-scale resin orders.
Expected to be completed in Q4 2023, the facility, located in Canton, Massachusetts, will provide significantly increased manufacturing and warehousing capacity. Hosting a variety of workspaces, including cleanroom laboratories for column packing services, offices, warehousing, and column assembly spaces, the facility will provide a vital hub to Astrea Bio’s North American supply network, as well as locally available technical expertise and customer support.
Dedicated column packing cleanrooms will increase production capacity for pre-packed column products and services. Increased warehousing space will be available for all products, including the company’s broad range of affinity, hydrophobic interaction chromatography and ion exchange adsorbents and resins for commercial-scale biologic production, and its AstreAdept range of nanofiber-based purification technology for production of cell and gene therapies.
Chris Brown, Operations Director, Astrea Bioseperations
